Patents by Inventor John NEUSTADT

John NEUSTADT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMENS AND METHODS FOR TREATING OR PREVENTING ACUTE MYELOID LEUKEMIA
    Publication number: 20120309845
    Abstract: The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating acute myeloid leukemia in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone.
    Type: Application
    Filed: June 1, 2011
    Publication date: December 6, 2012
    Applicant: NBI Pharmaceuticals, Inc.
    Inventors: John NEUSTADT, Steve PIECZENIK
  • DOSING REGIMENS AND METHODS FOR TREATING OR PREVENTING PROMYELOCYTIC LEUKEMIA
    Publication number: 20120309847
    Abstract: The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating promyelocytic leukemia in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone.
    Type: Application
    Filed: June 1, 2011
    Publication date: December 6, 2012
    Applicant: NBI Pharmaceuticals, Inc.
    Inventors: John NEUSTADT, Steve PIECZENIK
  • DOSING REGIMENS AND METHODS FOR TREATING OR PREVENTING MYELODYSPLASTIC SYNDROME
    Publication number: 20120309846
    Abstract: The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating myelodysplastic syndrome in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone.
    Type: Application
    Filed: June 1, 2011
    Publication date: December 6, 2012
    Applicant: NBI Pharmaceuitcals, Inc.
    Inventors: John NEUSTADT, Steve PIECZENIK
  • DOSING REGIMENS AND METHODS FOR TREATING OR PREVENTING HEPATOCELLULAR CARCINOMA
    Publication number: 20120309744
    Abstract: The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating hepatocellular adenocarcinoma in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone.
    Type: Application
    Filed: June 1, 2011
    Publication date: December 6, 2012
    Applicant: NBI Pharmaceuticals, Inc.
    Inventors: John NEUSTADT, Steve PIECZENIK